ASP Isotopes (NASDAQ: ASPI) hosted its first Capital Markets Day in London on September 8, 2026 — a closely watched event for investors tracking one of the most active companies in the production of critical isotopes for the nuclear sector. CEO and Executive Chairman Paul Mann summed up the moment with a pointed statement: in 2026, the company moved from building to producing.
The event was held in person, by invitation, with public access via webcast. Management outlined a strategy built around four pillars: nuclear medicine, electronics and industrial gases, helium and LNG, and nuclear fuels. On the nuclear front, the central focus is the fuel supply chain for advanced reactors, small modular reactors (SMRs), and fusion systems — all fast-growing segments where demand for enriched materials is outpacing current supply.
ASP Isotopes operates isotope enrichment facilities in Pretoria, South Africa, where it concentrates on producing light isotopes with low atomic mass. The two proprietary technologies at the heart of its industrial model are the aerodynamic separation process — known as ASP technology — and Quantum Enrichment, designed to improve separation efficiency beyond conventional methods. Both aim to drive down production costs and make the commercial-scale supply of critical isotopes economically viable.
On the partnerships front, the company has established agreements with Fermi America and the South Africa Nuclear Energy Corporation (Necsa) to accelerate the commercialisation of critical materials. The Necsa collaboration is particularly significant: the South African state entity has well-established infrastructure across the nuclear fuel cycle, and the operational synergies with ASP Isotopes could substantially shorten the path to scale. Over the past twelve months, the group has completed its transition to initial commercialisation across several business segments — a milestone that few companies in the sector manage while keeping costs under control.
The Capital Markets Day also provided context for a broader corporate transaction: ASP Isotopes is advancing a merger proposal involving ENDRA Life Sciences, subsidiary Renergen — which holds a 94.5% stake in Tetra4, active in natural gas and helium production in South Africa — and Noble Africa. The process includes the filing of a Form S-4 registration statement with the SEC, along with a prospectus and proxy statement for ENDRA shareholders. It is a complex corporate structure that reflects the group’s diversification across enriched isotopes for nuclear applications, helium for industrial and cryogenic uses, and liquefied natural gas.
The next twelve months will be the real test. ASP Isotopes has set concrete production targets for the commercial supply of enriched isotopes, the advancement of the Virginia Gas Project to Phase 2 with involvement from the U.S. International Development Finance Corporation, and the potential separate listing of certain divisions. If the transition from laboratory to market consolidates on the stated timeline, the company could emerge as a key supplier in the next-generation nuclear fuel supply chain on a global scale.
